Health Care • Medical Specialities
$30.79 ▲ +0.31
(+1.02%)
MKT CAP: $9.50B • VOL: 3.51M
52W L $11 52W H $35
OSCR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $28.6M | $20.6M | $21.4M |
| YoY Revenue Growth % | +39.0% | -3.6% | — |
| Gross Profit | $12.6M | $9.1M | $9.4M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$396.4M | $57.3M | -$235.6M |
| Operating Margin % | -1386.2% | 278.3% | -1103.4% |
| Net Income (GAAP) | -$443.2M | $25.4M | -$270.7M |
| EBITDA (Normalized) | -$395.3M | $58.0M | -$234.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.09B | $978.2M | -$272.2M |
| Capital Expenditures (CapEx) | $1.3M | $925.9K | $960.9K |
| Free Cash Flow (FCF) | $1.09B | $977.3M | -$273.1M |
| FCF Margin % | 3824.6% | 4749.5% | -1279.1% |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% | -5.9% |
| Cash & Short-Term Equivalents | $2.77B | $1.53B | $574.9M |
| Total Debt (Short + Long Term) | $430.1M | $299.6M | $1.22B |
| Total Stockholders' Equity | $977.6M | $1.01B | $2.51B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OSCR.